The world’s most effective malaria vaccine was developed by British scientists.
Researchers at the University of Oxford and their partners reported their Phase IIb trial of a candidate malaria the R21 / Matrix-M vaccine showed 77% efficacy over 12 months.
This makes it the very first to achieve the 75% efficiency target specified by the World Health Organization.
The team behind the new jab hope that it can be approved for use within the next two years, building on the speed and lessons learned from the rapid development of COVID-19[female[feminine vaccines.
Adrian Hill, director of the Jenner Institute, and Lakshmi Mittal, professor of vaccinology at the University of Oxford, led research on the Oxford-AstraZeneca coronavirus vaccine.
As co-author of the paper, Professor Hill said: “With the commitment of our business partner, the Serum Institute of India, to manufacture at least 200 million doses per year in the years to come, the vaccine has the potential to have a large audience. impact on health if approval is obtained. “
He said he was “fairly confident” that the efficacy could be replicated in the next phase of the trial.
“And we and others have found that if you vaccinate right before the malaria season, you maybe get a 10% improvement or something like that in terms of effectiveness – it’s not yet released but will be released.” soon enough from another group, ”he said.
When asked if this was the most effective malaria vaccine in the world, Professor Hill said: “It is in the sense that no other vaccine has had a primary endpoint with efficacy of. more than 75%, yes.
“So we’re excited about it. But as you know, there is a final phase of testing to be done.”
Professor Hill said the team hoped to report the results of the final stage of the trial next year.
“Malaria killed at least four times as many people in Africa last year …
More information about this article Read More
This notice was published: 2021-04-23 06:27:00